- Home
- WF vs PODD Comparison
WF vs PODD Comparison
Compare WF & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WF | PODD |
|---|---|---|
| Founded | 1899 | 2000 |
| Country | South Korea | United States |
| Employees | 13279 | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 17.0B |
| IPO Year | 2003 | 2007 |
Fundamental Metrics
Financial Performance| Metric | WF | PODD |
|---|---|---|
| Price | $66.42 | $237.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $358.00 |
| AVG Volume (30 Days) | 77.0K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $17.92 | $24.33 |
| Revenue Next Year | $3.99 | $19.33 |
| P/E Ratio | ★ $9.03 | $69.44 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $29.44 | $230.08 |
| 52 Week High | $84.71 | $354.88 |
Technical Indicators
Market Signals| Indicator | WF | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 36.55 |
| Support Level | $51.38 | N/A |
| Resistance Level | N/A | $299.75 |
| Average True Range (ATR) | 2.47 | 8.38 |
| MACD | -2.18 | 0.50 |
| Stochastic Oscillator | 5.48 | 10.26 |
Price Performance
Historical ComparisonAbout WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.